Roggwil, January 2, 2022 – According to an evaluation of the International Journal of Audiology of case reports and cross-sectional studies, 15% of patients report tinnitus or a worsening of their pre-existing tinnitus after a COVID-19 infection. Other consequences can be vertigo and dizziness attacks. These symptoms are presumably caused by inflammation in the inner ear due to the virus.

Since the beginning of the pandemic, Resaphene has observed a significant increase in inquiries about its tinniwell from month to month. As of today, there have been 289 million infections worldwide, which generates an additional patient volume of 43.35 million. Resaphene Suisse AG is currently expanding its production capacities to meet the explosive increase in demand.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company founded in 2015 that has been selling a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG


Ms. Anke Rauterkus (Chief Executive Officer)

Bahnhofplatz 5

9322 Egnach


Switzerland

T. +41 714500668


a.rauterkus@resaphene.ch